01—Abstract
Summary
Summary of the 10-Q filed May 9, 2011. Cited figures are marked; the original filing is the authoritative source.
TASER International, Inc. (now Axon Enterprise, Inc.) reported a net income of $19,732a for the first quarter of 2011, a significant improvement from a net loss of $492,605 in the same period of 2010.
This turnaround was driven by a 3% decrease in net sales to $23.1 millionb, coupled with a reduction in operating expenses, particularly in sales, general, and administrative (SG&A) and research and development (R&D). While overall sales declined slightly, the company saw positive contributions from new products like AXON/EVIDENCE.com and XREP. Financially, the company maintained a healthy liquidity position with $41.6 million in cash, cash equivalents, and investments as of March 31, 2011.
Operating activities generated $4.3 millionc in cash, which, along with existing cash reserves, was sufficient to fund operations, strategic initiatives like a $12.5 million stock repurchase program, and capital expenditures. The company also reported no outstanding debt, with access to a $10 million line of credit.
02—Key points
Key Highlights
- Achieved profitability in Q1 2011 with a net income of $19,732, a significant improvement from a net loss of $492,605 in Q1 2010.
- Net sales slightly decreased by 3.0% to $23.1 million, impacted by fewer large international orders and the tapering of federal stimulus funding that boosted prior-year sales.
- Operating expenses were reduced, with SG&A down 9.3% and R&D expenses down 33.5%, contributing to the improved profitability.
- The company launched new products like AXON/EVIDENCE.com and XREP, which contributed $0.5 million in sales in Q1 2011.
- Maintained a strong liquidity position with $41.6 million in cash, cash equivalents, and investments as of March 31, 2011.
- Initiated a $12.5 million stock repurchase program, having repurchased $5.1 million worth of shares by the end of Q1 2011.
- No outstanding debt at quarter-end, with $4.1 million available under a $10 million line of credit.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2011, Axon Enterprise, Inc. kept $0.00.
- Revenue$23.1M100.0%
- Cost of revenue−$10.9M47.2%
- Gross profit$12.2M52.8%
- Operating costs−$12.1M52.3%
- Operating income$110,1850.5%
- Interest, other & tax−$90,4530.4%
- Net income$19,7320.1%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2011filed May 9, 2011Financial Statements
| Revenue | $23.12M |
| Cost of Revenue | $10.91M |
| Gross Profit | $12.21M |
| R&D Expenses | $2.75M |
| SG&A Expenses | $9.35M |
| Operating Income | $110K |
| Net Income | $20K |
| Shares Outstanding (Basic) | 62.41M |
| Shares Outstanding (Diluted) | 63.25M |
05—Questions
Frequently Asked Questions
What was the overall financial performance of TASER International in Q1 2011 compared to Q1 2010?
TASER International showed a significant turnaround in Q1 2011, reporting a net income of $19,732 compared to a net loss of $492,605 in the prior year's quarter. This improvement was driven by a slight decrease in net sales to $23.1 million and substantial reductions in operating expenses, particularly in SG&A and R&D.
How did the company's revenue generation perform in Q1 2011?
Net sales decreased by 3.0% to $23.1 million. This was primarily attributed to fewer large international orders and the absence of federal stimulus funding that had boosted sales in the prior year. However, new products like AXON/EVIDENCE.com and XREP began contributing to revenue, totaling $0.5 million.
What is the company's current financial health and liquidity?
The company maintained a strong financial position with $41.6 million in cash, cash equivalents, and investments as of March 31, 2011. Operating activities generated positive cash flow of $4.3 million. The company also had no outstanding debt and had access to a $10 million line of credit, with $4.1 million available.
Are there any significant legal proceedings or risks that investors should be aware of?
TASER International is involved in numerous product liability lawsuits alleging wrongful death or personal injury, with 51 pending cases at the time of filing. While the company believes these lawsuits will not materially affect its financial condition, the outcome of litigation is inherently uncertain. Additionally, the company noted a risk that the introduction of new product lines could negatively impact sales of existing ones.
06—Continue